Controlled supply of tocilizumab during the COVID-19 pandemic and its influence on the treatment of rheumatological patients
e202111109
Keywords:
Tocilizumab, Shortage, Intravenous, Subcutaneous, Rheumatology, COVID-19Abstract
Background: Intravenous (IV) tocilizumab has been used to stop the inflammatory phase of SARS-CoV-2 infection. To preserve the largest number of IV units for this use, the Spanish Agency for Medicines and Health Products (AEMPS) carried out a controlled supply of it and recommended the change to a subcutaneous presentation (SC) of tocilizumab or sarilumab in all those patients in IV tocilizumab treatment for rheumatologic indications. The objective of this study was to evaluate the change from IV tocilizumab to SC presentation due to its controlled supply during the COVID-19 pandemic.
Methods: Retrospective observational study of adult patients (>18 years old) under treatment with IV tocilizumab follow-up by the Rheumatology Service of the Hospital 12 de Octubre. The follow-up period was 3 months (March 2020-June 2020) and 39 patients were included in the study. Variables related to the patients and their treatment were collected. A descriptive analysis of the data was carried out.
Results: In 69.23% (n=27) of the patients, treatment was changed to SC tocilizumab (n=23) or sarilumab (n=4). 44% of patients (n=12) switched back to their original IV tocilizumab treatment. The reasons for stopping treatment with SC tocilizumab were: drug intolerance (n=4), disease worsening (n=4), and patient preference (n=1). Regarding sarilumab, the reasons were drug intolerance (n=2) and patient preference (n=1).
Conclusions: Almost half of the patients had to return to the original treatment. The main reason was intolerance to the new treatment, followed by ineffectiveness and patient preferences.
Downloads
References
Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med [Internet] 2020 [cited 2020 ago 31]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267177/
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239-42.
Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol [Internet] 2020 [cited 2020 ago 31]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323250/
Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol [Internet] 2020 [cited 2020 ago 31]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361342/
Gao Y-M, Xu G, Wang B, Liu B-C. Cytokine storm syndrome in coronavirus disease 2019: A narrative review. J Intern Med [Internet] 2020 [cited 2020 sep 6]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404514/
Behrens EM, Koretzky GA. Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era. Arthritis Rheumatol 2017;69(6):1135-43.
FICHA TECNICA ROACTEMRA 20 mg/ml, CONCENTRADO PARA SOLUCION PARA PERFUSION [Internet]. [citado 2020 ago 16]; Disponible en: https://cima.aemps.es/cima/dochtml/ft/08492001/FT_08492001.html
Ma Y, Wu M, Zhang X, Xia Q, Yang J, Xu S et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still’s disease: A meta-analysis. Mod Rheumatol 2018;28(5):849-57.
Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA 2016;315(22):2442-58.
Karkhur S, Hasanreisoglu M, Vigil E, Halim MS, Hassan M, Plaza C et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect 2019;9(1):17.
La COVID-19 y los pacientes con enfermedades reumáticas [Internet]. SER2020 [citado 2020 nov 23]; Disponible en: https://www.ser.es/el-coronavirus-covid-19-y-los-pacientes-con-enfermedades-reumaticas/
Gupta R, Shipa M, Yeoh S-A, Buck P, Ehrenstein MR. An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic. Rheumatology [Internet] 2020 [cited 2020 dic 9];(keaa653). Available from: https://doi.org/10.1093/rheumatology/keaa653
Darloy J, Segaud N, Salmon J-H, Eschard J-P, Goëb V, Deprez X et al. tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study. Rheumatol Ther 2019;6(1):61-75.
Lauper K, Mongin D, Iannone F, Klami Kristianslund E, Kvien TK, Nordström D et al. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. RMD Open [Internet] 2018 [cited 2020 sep 14];4(2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241977/
Fernández-Ruiz M, López-Medrano F, Pérez-Jacoiste Asín MA, Maestro de la Calle G, Bueno H, Caro-Teller JM et al. tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study. J Med Virol [Internet] 2020 [citado 2020 dic 21]; Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404673/
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. tocilizumab treatment in COVID-19: A single center experience. J Med Virol [Internet] 2020 [cited 2020 dic 21]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262125/
Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M et al. tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020;2(8):e474-84.
Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P et al. Effect of tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med [Internet] 2020 [cited 2020 dic 21]; Available from: https://doi.org/10.1001/jamainternmed.2020.6820
Parr JB. Time to Reassess tocilizumab’s Role in COVID-19 Pneumonia. JAMA Intern Med [Internet] 2020 [cited 2020 dic 21]; Available from: https://doi.org/10.1001/jamainternmed.2020.6557
Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L et al. Effect of tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med [Internet] 2020 [cited 2020 dic 21]; Available from: https://doi.org/10.1001/jamainternmed.2020.6615
Investigators TR-C, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report. medRxiv 2021;2021.01.07.21249390.
Kaminski MA, Sunny S, Balabayova K, Kaur A, Gupta A, Abdallah M et al. tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies. Int J Infect Dis IJID Off Publ Int Soc Infect Dis 2020;101:59-64.
Navas N, Hermosilla J, Torrente-López A, Hernández-Jiménez J, Cabeza J, Pérez-Robles R et al. Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes. J Pharm Anal [Internet] 2020 [cited 2020 dic 9]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319620/
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Sara Ortiz Pérez, José Manuel Caro Teller, Carmen García Muñoz, Paola Herraiz Robles, Fernando Lozano Morillo, José Luis Pablos Álvarez, José Miguel Ferrari Piquero
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
